Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIRM Mirum Pharmaceuticals	$98.62 -2.0%	$96.20	$42.89 ▼ $114.99	$6.01B	0.52	1.28 million shs	453,055 shs
NRIX Nurix Therapeutics	$17.50 -0.2%	$16.00	$8.19 ▼ $22.50	$1.81B	1.87	1.01 million shs	1.05 million shs
RYTM Rhythm Pharmaceuticals	$87.84 -2.6%	$87.27	$58.71 ▼ $122.20	$6.02B	1.94	778,742 shs	479,070 shs
SYRE Spyre Therapeutics	$74.05 -0.4%	$60.51	$13.93 ▼ $78.80	$6.43B	3.12	1.14 million shs	574,914 shs

10 Stocks Set to Soar in 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIRM Mirum Pharmaceuticals	-2.04%	-3.48%	+4.57%	-6.22%	+122.57%
NRIX Nurix Therapeutics	-0.17%	+10.41%	+5.23%	+10.90%	+78.94%
RYTM Rhythm Pharmaceuticals	-2.61%	-2.96%	+3.12%	-11.97%	+40.75%
SYRE Spyre Therapeutics	-0.36%	-1.16%	+1.44%	+71.37%	+401.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIRM Mirum Pharmaceuticals	$98.62 -2.0%	$96.20	$42.89 ▼ $114.99	$6.01B	0.52	1.28 million shs	453,055 shs
NRIX Nurix Therapeutics	$17.50 -0.2%	$16.00	$8.19 ▼ $22.50	$1.81B	1.87	1.01 million shs	1.05 million shs
RYTM Rhythm Pharmaceuticals	$87.84 -2.6%	$87.27	$58.71 ▼ $122.20	$6.02B	1.94	778,742 shs	479,070 shs
SYRE Spyre Therapeutics	$74.05 -0.4%	$60.51	$13.93 ▼ $78.80	$6.43B	3.12	1.14 million shs	574,914 shs

10 Stocks Set to Soar in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIRM Mirum Pharmaceuticals	-2.04%	-3.48%	+4.57%	-6.22%	+122.57%
NRIX Nurix Therapeutics	-0.17%	+10.41%	+5.23%	+10.90%	+78.94%
RYTM Rhythm Pharmaceuticals	-2.61%	-2.96%	+3.12%	-11.97%	+40.75%
SYRE Spyre Therapeutics	-0.36%	-1.16%	+1.44%	+71.37%	+401.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MIRM Mirum Pharmaceuticals	3.00	Buy	$137.08	39.00% Upside
NRIX Nurix Therapeutics	2.93	Moderate Buy	$30.46	74.07% Upside
RYTM Rhythm Pharmaceuticals	2.84	Moderate Buy	$131.81	50.06% Upside
SYRE Spyre Therapeutics	3.00	Buy	$90.25	21.88% Upside

Current Analyst Ratings Breakdown

Latest NRIX, SYRE, MIRM, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2026	MIRM Mirum Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$145.00
5/19/2026	MIRM Mirum Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy	$145.00
5/18/2026	NRIX Nurix Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00
5/12/2026	SYRE Spyre Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$102.00
5/7/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
5/7/2026	MIRM Mirum Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$128.00 ➝ $142.00
5/7/2026	MIRM Mirum Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$125.00 ➝ $145.00
5/7/2026	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$165.00
5/7/2026	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$185.00
5/7/2026	MIRM Mirum Pharmaceuticals	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$138.00
5/7/2026	MIRM Mirum Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$136.00

(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MIRM Mirum Pharmaceuticals	$521.31M	11.54	$0.05 per share	1,974.73	$3.98 per share	24.78
NRIX Nurix Therapeutics	$83.98M	21.55	N/A	N/A	$5.29 per share	3.31
RYTM Rhythm Pharmaceuticals	$217.17M	27.72	N/A	N/A	$1.79 per share	49.07
SYRE Spyre Therapeutics	$890K	7,225.28	N/A	N/A	$5.93 per share	12.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MIRM Mirum Pharmaceuticals	-$23.36M	-$13.61	N/A	340.07	N/A	-140.24%	-11.28%	-3.84%	7/30/2026 (Estimated)
NRIX Nurix Therapeutics	-$264.46M	-$3.16	N/A	N/A	N/A	-411.37%	-64.21%	-48.44%	7/9/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.13	N/A	N/A	N/A	-93.33%	-203.25%	-44.99%	8/4/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$2.08	N/A	N/A	N/A	N/A	-42.88%	-27.76%	8/4/2026 (Estimated)

Latest NRIX, SYRE, MIRM, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	MIRM Mirum Pharmaceuticals	-$0.75	-$13.43	-$12.68	-$13.43	$148.21 million	$159.88 million
5/5/2026	Q1 2026	RYTM Rhythm Pharmaceuticals	-$0.86	-$0.83	+$0.03	-$0.83	$55.78 million	$60.11 million
5/5/2026	Q1 2026	SYRE Spyre Therapeutics	-$0.66	-$0.74	-$0.08	-$0.74	$70.87 million	N/A
4/8/2026	Q1 2026	NRIX Nurix Therapeutics	-$0.76	-$0.79	-$0.03	-$0.79	$14.25 million	$6.25 million
2/26/2026	Q4 2025	RYTM Rhythm Pharmaceuticals	-$0.79	-$0.73	+$0.06	-$0.73	$56.16 million	$57.25 million
2/25/2026	Q4 2025	MIRM Mirum Pharmaceuticals	$0.02	-$0.11	-$0.13	-$0.12	$141.78 million	$148.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MIRM Mirum Pharmaceuticals	1.28	2.09	1.99
NRIX Nurix Therapeutics	N/A	6.01	6.01
RYTM Rhythm Pharmaceuticals	N/A	4.17	3.89
SYRE Spyre Therapeutics	N/A	8.97	8.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MIRM Mirum Pharmaceuticals	N/A
NRIX Nurix Therapeutics	N/A
RYTM Rhythm Pharmaceuticals	N/A
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
MIRM Mirum Pharmaceuticals	14.36%
NRIX Nurix Therapeutics	6.70%
RYTM Rhythm Pharmaceuticals	5.90%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MIRM Mirum Pharmaceuticals	140	60.98 million	52.22 million	Optionable
NRIX Nurix Therapeutics	300	103.41 million	96.48 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable
SYRE Spyre Therapeutics	73	86.84 million	73.22 million	Optionable

NRIX, SYRE, MIRM, and RYTM Headlines

Recent News About These Companies

PSP Research LLC Takes Position in Spyre Therapeutics, Inc. $SYRE

May 20 at 6:20 AM | marketbeat.com

LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)

May 18, 2026 | theglobeandmail.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Buy" from Analysts

May 13, 2026 | americanbankingnews.com

UBS Group AG Has $22.30 Million Stake in Spyre Therapeutics, Inc. $SYRE

May 12, 2026 | marketbeat.com

Vanguard Group Inc. Has $132.19 Million Stock Position in Spyre Therapeutics, Inc. $SYRE

May 12, 2026 | marketbeat.com

State of New Jersey Common Pension Fund D Invests $547,000 in Spyre Therapeutics, Inc. $SYRE

May 12, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year High - Time to Buy?

May 11, 2026 | marketbeat.com

F m Investments LLC Acquires 48,825 Shares of Spyre Therapeutics, Inc. $SYRE

May 10, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Director Sells $5,952,000.00 in Stock

May 9, 2026 | insidertrades.com

Michael Thomas Henderson Sells 80,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

May 8, 2026 | marketbeat.com

Spyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on Thursday

May 7, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $97.00 at Citigroup

May 6, 2026 | marketbeat.com

Spyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for Stockholders

May 6, 2026 | tipranks.com

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026 | globenewswire.com

Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $892,125.00 in Stock

May 2, 2026 | insidertrades.com

Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million Raise

May 1, 2026 | finance.yahoo.com

Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells 12,500 Shares of Stock

May 1, 2026 | marketbeat.com

Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock

May 1, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $5,600,809.50 in Stock

May 1, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Trading Down 6.3% - Here's What Happened

May 1, 2026 | marketbeat.com

Spyre Therapeutics Announces Grants of Inducement Awards

May 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NRIX, SYRE, MIRM, and RYTM Company Descriptions

Mirum Pharmaceuticals NASDAQ:MIRM

$98.62 -2.05 (-2.04%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$98.58 -0.04 (-0.04%)

As of 05/22/2026 05:29 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Nurix Therapeutics NASDAQ:NRIX

$17.50 -0.03 (-0.17%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$17.03 -0.47 (-2.71%)

As of 05/22/2026 05:39 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$87.84 -2.35 (-2.61%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$86.42 -1.43 (-1.62%)

As of 05/22/2026 05:05 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Spyre Therapeutics NASDAQ:SYRE

$74.05 -0.27 (-0.36%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$73.40 -0.65 (-0.88%)

As of 05/22/2026 07:06 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRIX, SYRE, MIRM, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRIX, SYRE, MIRM, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRIX, SYRE, MIRM, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NRIX, SYRE, MIRM, and RYTM Company Descriptions

Mirum Pharmaceuticals NASDAQ:MIRM

Nurix Therapeutics NASDAQ:NRIX

Rhythm Pharmaceuticals NASDAQ:RYTM

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRIX, SYRE, MIRM, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRIX, SYRE, MIRM, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRIX, SYRE, MIRM, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NRIX, SYRE, MIRM, and RYTM Company Descriptions

Mirum Pharmaceuticals NASDAQ:MIRM

Nurix Therapeutics NASDAQ:NRIX

Rhythm Pharmaceuticals NASDAQ:RYTM

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools